Onxeo S.A. buy Mori8
Summary
This prediction ended on 09.07.21 with a price of €0.61. The BUY prediction by Mori8 finished with a performance of 4.97%. Mori8 has 50% into this predictionOnxeo is a cutting-edge biotechnology company that specializes in the research and development of novel drugs to treat patients with rare or resistant cancers. Headquartered in Paris, France, this innovative firm has established itself as a leader in the field by leveraging its advanced platform, known as DNA Therapeutics, in conjunction with a comprehensive portfolio of small molecules and orphan oncology assets. With a strong commitment to scientific excellence and a robust intellectual property strategy, Onxeo aims to improve patient outcomes by addressing critical unmet medical needs and creating value for stakeholders through strategic partnerships and licensing deals.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Onxeo S.A. | -2.969% | -2.969% | -62.864% | -86.474% |
iShares Core DAX® | 1.665% | 1.692% | 18.093% | 15.353% |
iShares Nasdaq 100 | -0.475% | 1.483% | 27.860% | 36.314% |
iShares Nikkei 225® | 2.620% | 4.475% | 17.651% | 10.750% |
iShares S&P 500 | -0.091% | 1.099% | 24.873% | 36.740% |
Comments by Mori8 for this prediction
In the thread Onxeo S.A. diskutieren
Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties
Marktkapitalisierung | 56 Mio. €
Trotz der Einschränkungen, die durch die anhaltende COVID-19-Pandemie verursacht wurden, ist es Onxeo gelungen, eine neue Phase-Ib / II-REVOCAN-Studie bei rezidiviertem Eierstockkrebs einzuleiten, in der die potenziell einzigartige Fähigkeit von AsiDNA bewertet wird, die Tumorresistenz gegen den PARP-Inhibitor Niraparib umzukehren.
In the thread Trading Onxeo S.A.